Drugs / ABBV-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06887010 | Mar → Sep 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05753501 | Jun 2023 → Mar 2031 expected | hematopoietic and lymphoid cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06887010 ↗ |
| Modality | Other / unclassified | “BTK Degrader” NCT05753501 ↗ |
| Route | Oral | “Oral:Tablet” NCT05753501 ↗ |
| Target | BTK | “BTK Degrader” NCT05753501 ↗ |